ImageneBio, Inc.
ImageneBio (Nasdaq: IMA) reported Q2 2026 results for the quarter ended June 30, 2026, and updated its lead drug olevaprubart (IMG-007). The Phase 2b ADAPTIVE trial in atopic dermatitis continues under an amended protocol, with topline data expected in Q4 2027. Cash was $136.2M, funding operations into Q1 2028. R&D was $6.7M and net loss $10.2M ($0.63/share).
ImageneBio, Inc. (IMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d166048dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImageneBio Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 5, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended June 30,
ImageneBio, Inc. (IMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d143178dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 I MAGENE B IO , I NC . S EVERANCE AND C HANGE IN C ONTROL P LAN Section 1. I NTRODUCTION . The ImageneBio, Inc. Severance and Change in Control Plan (the “ Plan ”) is hereby established by the Compensation Committee of the
Over the past 7 days, alphai's AI scored 2 news stories mentioning IMA (ImageneBio, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent IMA coverage spans corporate actions, earnings and financial news.
In the last 30 days, IMA insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($17K). The most active reporter was Lally Robert B, Principal Accounting Officer, with 2 filings.
The update reinforces clinical progress and extends runway via cash, but provides no new efficacy readout yet (topline still expected Q4 2027).
The filing reinforces clinical progression and extends the funding runway, reducing near-term financing risk while keeping the key catalyst as Q4 2027 topline.
This is a corporate governance and executive compensation filing, not an operational or financial update.
Board/officer turnover raises near-term execution and accounting/controls continuity questions until a replacement is named.
Equity-plan amendments can increase future dilution and affect valuation/option overhang expectations, but this filing contains no new earnings or guidance.
alphai scores every news story that mentions IMA with an AI model for sentiment and relevance, and aggregates insider trades from ImageneBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ImageneBio (Nasdaq: IMA) reported Q2 2026 results for the quarter ended June 30, 2026, and updated its lead drug olevaprubart (IMG-007). The Phase 2b ADAPTIVE trial in atopic dermatitis continues under an amended protocol, with topline data expected in Q4 2027. Cash was $136.2M, funding operations into Q1 2028. R&D was $6.7M and net loss $10.2M ($0.63/share).
6 min readImageneBio, Inc. (IMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d166048dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImageneBio Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 5, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended June 30,
6 min readImageneBio, Inc. (IMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d143178dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 I MAGENE B IO , I NC . S EVERANCE AND C HANGE IN C ONTROL P LAN Section 1. I NTRODUCTION . The ImageneBio, Inc. Severance and Change in Control Plan (the “ Plan ”) is hereby established by the Compensation Committee of the
2 min readImageneBio, Inc. (IMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001835579 0001835579 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
2 min readImageneBio, Inc. (IMA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d114862dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 I MAGENE B IO , I NC . A MENDED AND R ESTATED 2025 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : D ECEMBER 12, 2024 A PPROVED BY THE S TOCKHOLDERS : J ULY 15, 2025 A MENDED AND R ESTATED BY THE B OARD OF D
3 min read$142.6 million cash and cash equivalents and marketable securities as of September ...
4 min readSAN DIEGO, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ImageneBio, Inc. ( Nasdaq: IMA ) ( "ImageneBio" ) , a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory ( "I&I" ) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's ...
2 min read